TrialVaccine2010

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Alfred von Krempelhuber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.